{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T19:46:58Z","timestamp":1718567218250},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0139873","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T17:21:19Z","timestamp":1444238479000},"page":"e0139873","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomized, Controlled, Thorough QT\/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects"],"prefix":"10.1371","volume":"10","author":[{"given":"Yuji","family":"Kumagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Hasunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshishige","family":"Samukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","article-title":"(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS\u2013071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment","volume":"53","author":"H Kakinuma","year":"2010","journal-title":"J Med Chem"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2011.01340.x","article-title":"TS\u2013071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity","volume":"164","author":"K Yamamoto","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/13543784.2013.774372","article-title":"Differentiating sodium-glucose co-transporter\u20132 inhibitors in development for the treatment of type 2 diabetes mellitus","volume":"22","author":"WN Washburn","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/dmrr.2403","article-title":"Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus","volume":"29","author":"P Raskin","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12325-014-0102-3","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial","volume":"31","author":"T Sasaki","year":"2014","journal-title":"Adv Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12325-015-0200-x","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial","volume":"32","author":"T Sasaki","year":"2015","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"N Sarwar","year":"2010","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/DMSO.S35682","article-title":"Teneligliptin: a DPP\u20134 inhibitor for the treatment of type 2 diabetes","volume":"6","author":"M Kishimoto","year":"2013","journal-title":"Diabetes Metab Syndr Obes Target Ther"},{"key":"ref9","unstructured":"ICH E14. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. International Conference of Harmonisation Step 4 Guideline, EMEA, CHMP\/ICH\/2\/04. 25-5-2005."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance","volume":"159","author":"B Darpo","year":"2010","journal-title":"Br J Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/0091270009337511","article-title":"A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects","volume":"49","author":"DM Bloomfield","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"ref12","article-title":"Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, Phase II study","author":"Y Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"ref13","article-title":"Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study","author":"Y Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"supplement(s1)","key":"ref14","first-page":"A275","article-title":"Effect of gender and age on the pharmacokinetics of luseogliflozin (TS\u2013071), a selective SGLT2 inhibitor [abstract]","volume":"61","author":"T Sasaki","year":"2012","journal-title":"Diabetes"},{"issue":"supplement(1)","key":"ref15","first-page":"S303","article-title":"Luseogliflozin (TS\u2013071), a selective SGLT2 inhibitor, improves glycemic control in Japanese type 2 diabetic subjects with renal impairment [abstract]","volume":"55","author":"M Haneda","year":"2012","journal-title":"Diabetologia"},{"issue":"supplement(s1)","key":"ref16","first-page":"228","article-title":"Drug-drug interactions of luseogliflozin (TS\u2013071) with other oral hypoglycemic agents in healthy Japanese subjects [abstract]","volume":"3","author":"T Sasaki","year":"2012","journal-title":"J Diabetes Investig"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","article-title":"Effects of three fluoroquinolones on QT interval in healthy adults after single doses","volume":"73","author":"GJ Noel","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","article-title":"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects","volume":"68","author":"JL D\u00e9molis","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2125.2006.02793.x","article-title":"Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects","volume":"63","author":"JG Shin","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2125.2011.04110.x","article-title":"Comparison of the effects of levofloxacin on QT\/QTc interval assessed in both healthy Japanese and Caucasian subjects","volume":"73","author":"A Sugiyama","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2008.33","article-title":"The effect of moxifloxacin on QTc and implications for the design of thorough QT studies","volume":"84","author":"DM Bloomfield","year":"2008","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0139873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T08:36:35Z","timestamp":1540024595000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0139873"}},"subtitle":[],"editor":[{"given":"Renate B","family":"Schnabel","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0139873","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]}}}